| Literature DB >> 15642351 |
Masashi Morita1, Ikuko Takahashi, Mariko Kanai, Fumito Okafuji, Makoto Iwashima, Toshimitsu Hayashi, Shiro Watanabe, Tomohito Hamazaki, Nobuyuki Shimozawa, Yasuyuki Suzuki, Hirokazu Furuya, Takeshi Yamada, Tsuneo Imanaka.
Abstract
The purpose of the present study is to identify bioactive compounds with potential for X-linked adrenoleukodystrophy (X-ALD) pharmacological therapy. Various plant natural products including flavonoids were tested for their ability to ameliorate the abnormality of very long chain fatty acid (VLCFA) metabolism in cultured skin-fibroblasts from X-ALD patients. Of the compounds tested, baicalein 5,6,7-trimethyl ether (baicalein-tri-Me) was found to significantly stimulate the VLCFA beta-oxidation activity. Furthermore, the incorporation of [1-(14)C]lignoceric acid into cholesteryl esters was markedly reduced towards the normal level and the VLCFA (C24:0 and C26:0) content was decreased. These results make baicalein-tri-Me a candidate for the therapeutic compound for X-ALD.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15642351 DOI: 10.1016/j.febslet.2004.11.102
Source DB: PubMed Journal: FEBS Lett ISSN: 0014-5793 Impact factor: 4.124